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Discovery of a Novel Family of CDK Inhibitors
with the Program LIDAEUS: Structural Basis for
Ligand-Induced Disordering of the Activation Loop
of the cell cycle, D-type cyclins form complexes with
CDK4 and CDK6, and then CDK2 is activated through
association with cyclin E. In S phase, however, cyclin A
binds CDK2, and, in the G2/M phase, cyclin B complexes
with CDK1. Activation of CDK2 by cyclin E is thought
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and Malcolm D. Walkinshaw1,2,* to be a crucial step in the progression from G1 to S
phase, and CDK2 is thus a principal target for inhibitory1Structural Biochemistry Group
The University of Edinburgh drugs. It should be noted that not all members of the
CDK family are involved exclusively in cell cycle control.Michael Swann Building
King’s Buildings Thus, CDKs 7, 8, and 9 are implicated in the regulation
of transcription, and CDK5 plays a role in neuronal andEdinburgh, EH9 3JR
United Kingdom secretory cell function [5]. Some five different chemical
classes of CDK2 inhibitors have been discovered to2 Cyclacel Ltd.
James Lindsay Place date, and representative members have all been studied
by X-ray crystallography. The inhibitor indirubin hasDundee, DD1 5JJ
United Kingdom been shown to be the active principle in a traditional
Chinese herbal medicine used to treat myelocytic leuke-
mia [6]. Furthermore, several CDK2 inhibitors, including
flavopiridol and CYC202 (an enantiomerically pure formSummary
of roscovitine [7]) have already reached the stage of
clinical trials; results are encouraging and clearly showA family of 4-heteroaryl-2-amino-pyrimidine CDK2 in-
hibitor lead compounds was discovered with the new the validity of CDKs as anticancer targets [8].
We have used the database-mining program LIDAEUSdatabase-mining program LIDAEUS through in silico
screening. Four compounds with IC50 values ranging to search for new chemical families of CDK inhibitors.
LIDAEUS has evolved from our previous programs San-from 17 to 0.9M were selected for X-ray crystal analy-
sis. Two distinct binding modes are observed, one dock [9] and Probis [10]. The screening procedure uses
a database of small-molecule 3D structures by fittingof which resembles the hydrogen bonding pattern of
bound ATP. In the second binding mode, the ligands ligand atoms of each test structure onto site points rep-
resenting the physicochemical nature and structure oftrigger a conformational change in the activation T
loop by inducing movement of Lys33 and Asp145 side the enzyme active site. The strength of protein-ligand
binding depends on the complementarity of shape andchains. The family of molecules discovered provides
an excellent starting point for the design and synthesis charge between the ligand and the protein receptor site,
as well as a number of entropic factors, including theof tight binding inhibitors, which may lead to a new
class of antiproliferative drugs. flexibility of the ligand and, also, the displacement of
water from the ligand binding site [11]. Scoring functions
incorporating some of these terms provide a measureIntroduction
of goodness of fit for the docking of the test ligands.
The program also applies a fast flexible conformationalCancer cells generally have corrupt cell cycle regulation,
resulting in the loss of control of orderly cell division. A search to each ligand. This approach avoids the need
for generating large multiconformer databases.particularly important therapeutic cell cycle target pro-
tein class is the CDK family [1], members of which phos- Here we describe our screening approach based on
the known 3D structure of CDK2. Biochemical screeningphorylate key cellular components required for prolifera-
tion and whose activity is deregulated in many tumor of less than 200 compounds virtually selected from a
ca. 50,000-member drug-like small-molecule collectioncells [2]. In fact, abnormal phosphorylation of cellular
proteins is a hallmark of disease in general, and, for this afforded modestly potent enzyme inhibitor hits. We used
protein X-ray crystallography to determine the structuralreason, there has been a growing interest in the use of
protein kinase inhibitors as drugs. Inhibitors against basis for the biochemically verified CDK2 inhibition of
three structurally related lead compounds from the inboth tyrosine and serine/threonine kinases are being
developed for cancer and other proliferative diseases silico screening output. Furthermore, we show how this
information was used in the structure-based design of[3]. CDK activities are modulated throughout the cell
cycle by various members of the cyclin protein family. a novel prototype second generation ATP antagonist
compound with selectivity and submicromolar potencyThe CDK apoenzymes are practically devoid of biologi-
cal activity and require both specific activating phos- against CDK2, as well as antiproliferative activity against
tumor cells both in vitro and in vivo. Again, the hypotheti-phorylations, e.g., by the CDK-activating kinase (itself
a CDK complex, CDK7/cyclin H) and complex formation cal binding mode used for the design of this compound
was confirmed experimentally. Finally, the bindingwith cyclins for full kinase activity [4]. In the G1 phase
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Figure 1. Illustration of LIDAEUS Site Point
Generation
The CDK2/ATP complex is shown on the left,
and an exploded view of the bound orienta-
tion of staurosporine, together with the site
points generated, is depicted on the right.
modes of our new class of inhibitors are compared with according to a combination of properties (usually en-
thalpy of interaction and buriedness), and the changingpublished X-ray structures of other CDK inhibitor fami-
list of top hits can be viewed during the calculation. Alies. In the structures presented here, an interesting cor-
rigid-body energy minimization of the top hits providesrelation is observed, which also holds good for other
the final ranked list of hits.published CDK2 structures, showing that certain classes
Identification of a New CDK2 Inhibitor Pharmacophoreof ligands induce a conformational change in the T loop
We applied these procedures to a 3D-encoded databaseby disturbing the side chain conformations of Lys33 and
of ca. 50,000 commercially available drug-like mole-Asp145.
cules. In a first round, the predicted top-ranking 120
compounds were screened at a fixed concentration ofResults and Discussion
5 M, by an in vitro CDK2/cyclin E protein kinase assay.
Of these, 17 (14%) displayed significant inhibition at thatDatabase Mining and Lead Discovery
concentration. Rescreening to obtain full dose-responseWe have applied a new virtual-screening computer pro-
curves showed that six (5%) of these compounds inhib-gram (LIDAEUS) for the automated docking of small
ited CDK2/cyclin E with IC50 values below 20 M. In aligands to the active site of CDK2. With this approach,
second round of in silico screening, the LIDAEUS param-
orientations of the ligand in the active site are generated
eters were adjusted with a more complete description
such that a chemical and a shape complementarity be-
of the van der Waals interactions between protein and
tween the ligand and the active site cavity have to be ligand. Again, the entire small-molecule database was
fulfilled. The generated fits are evaluated with scoring processed, and the top 28-ranked compounds were
functions that account for van der Waals, hydrophobic, screened in vitro. This time a control panel of 28 ran-
and H bonding interactions. This newly developed dock- domly selected compounds from the same chemical
ing program can efficiently screen very large databases library was included in order to ascertain that the virtual
in a reasonable time. LIDAEUS constructs a cubic grid screen did in fact result in above-random hit enrichment.
of points in the putative binding pocket of the protein; The results obtained suggested that the program is very
in our application, this was based on the known CDK2/ useful in the initial stages of screening a library of com-
staurosporine enzyme inhibitor complex (Figure 1). Each pounds. Once the LIDAEUS parameters were optimized
grid point has associated calculated properties, includ- for CDK2, our hit rate increased from 7% (randomly se-
ing van der Waals interaction energy, H bonding capac- lected) to 29% of the compounds chosen by the LIDAEUS
ity, and buriedness. We refer to the subset of grid points program (using a cutoff of 30% inhibition at a fixed
with their associated properties as site points. inhibitor concentration of 30 M for the screen).
Three-dimensional databases of small molecules are Using the screening approach described, we identi-
screened to find potential ligands. The first step in the fied several groups of structurally related compounds
docking procedure is to match the atom properties of representing putative CDK2/4 ATP antagonist pharma-
the potential ligand with the calculated values of the cophores. One of these groups consisted of 2-amino-
site points. Any number of point to atom fits may be 4-heteroaryl-pyrimidines (Table 1; CYC1–CYC3). Biolog-
requested; however, the more points requested, the ical activity data for these compounds are summarized
more computer time is required per compound. A good in Table 2. The compounds were also cross-screened
geometric and property match of four atoms with four against CDK4/cyclin D1, PKC, and ERK-2. No signifi-
points provides a viable initial hit. All ligand-protein con- cant crossreaction with the non-CDK kinases was ob-
tacts are then tested to ensure that there are no severe served, although inhibition of the structurally similar
steric clashes between ligand and protein. All ligand hits CDK4 was seen, as is the case with most ATP-antago-
nistic CDK inhibitor compounds [12]. Although the com-are ranked according to scores that can be weighted
Structures of a Novel Family of CDK2 Inhibitors
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Table 1. Relationship between H Bond Pattern, Orientation of K33, and Disorder in the Activation T Loop
Protein Data
Ligand Bank Code Structure H Bond Mode K33 Orientation (1 []) T Loop
None 1HCL [14] — — Gauche (55) Ordered
ATP 1HCK [14] I 1 Trans (173) Disordered
CYC1 This study II 1 Gauche (48) Ordered
CYC2 This study III 1 Gauche (37) Ordered
CYC3 This study IV 2 Trans (171) Disordered
CYC4 This study V 2 Trans (179) Disordered
Roscovitine NC [19] VI; R, iPr; R, NHCH(Et)CH2OH; R″, -Bn 2 NC NC
Purvalanol B 1CKP [17] VI; R, iPr; R, NHCH(iPr)CH2OH; R″, 2 Trans (173) Disordered
3-Cl-4-COOH-Ph
H717 1G5S [18] VI; R, cycloBu; R, 1,4-di-NH2-cyclohexyl; 2 Trans (179) Disordered
R″, Bn
OL567 NC [20] VI; R, iPr; R, CCC(Me)(Et)OH; R″, 2 NC NC
4-MeO-Bn
NU2058 1E1V [21] VII 1 Gauche (56) Ordered
Indirubin-5-sulfonate 1E9H [30] VIII 2 (Cyclin bound) Ordered
Pyridopyrimidinone NC [23] IX 2 NC NC
Anilinoquinazoline 1DI8 [42] X 2 Trans (169) Disordered
Flavopiridol NC [43] XI 1 NC NC
Oxindole 1FVT [22] XII Trans (160) Disordered
Pyridinylurea 1GIH [44] XIII 1 Trans (172) Disordered
Staurosporine 1AQ1 [45] XIV Trans (179) Disordered
Hymenialdisine 1DM2 [46] XV Trans (174) Disordered
CDK2 inhibitors of known structure are drawn in a similar orientation to those in Figure 4, where the hydrogen bonds are shown. H bonds to
atoms E81 CO, L83 CO, and L83 HN are denoted by red, blue, and green atoms.
NC, no coordinates have been made available; Disordered, the B factor for Thr160 is greater than 90 A˚2 or the coordinates have been omitted
from the Protein Data Bank file.
pounds are modestly potent CDK inhibitors, one of them Lead Optimization
Compound CYC4 (Table 1) was designed on the basis(CYC1) exhibited some antiproliferative activity against
human tumor cell lines. of the experimentally observed binding modes of com-
Table 2. Biological Activity of Lead Compounds
Kinase Inhibition, IC50 (M) In Vitro Antiproliferative Activity, IC50 (M)
Compound CDK2/Cyclin E CDK4/Cyclin D1 Transformed Cells Normal Cells
CYC1 17 3.1 30 100
CYC2 13 30 100 100
CYC3 2.2 27 100 100
CYC4 0.9 5.5 1.5 10
The ATP concentration in the kinase assays was 100 M. Human tumor cell lines (transformed) were A549, HT29, and Saos-2. Nontransformed
(normal) human cell lines were Hs27, IMR90, and WI38. Antiproliferative activity was measured by the 72 hr MTT assay.
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Table 3. Cytotoxic Activity of Compound CYC4 on Human Tumor Cell Lines
Tumor Cell Line
Name Tissue Type 96 hr MTT IC50 (M)
A549 Lung Carcinoma 2.4
ChaGo-K-1 Lung Bronchogenic carcinoma 0.5
NCI-H460 Lung Large-cell lung cancer 14.0
LoVo Colon Colorectal adenocarcinoma 1.1
HCT-15 Colon Colorectal adenocarcinoma 1.0
HCT 116 Colon Colorectal adenocarcinoma 0.7
HT-29 Colon Colorectal adenocarcinoma 0.5
A498 Kidney Carcinoma 4.8
ACHN Kidney Renal cell adenocarcinoma 3.0
HT-1376 Bladder Urinary carcinoma 9.2
MCF7 Breast Adenocarcinoma 0.8
MDA-MB-435S Breast Ductal carcinoma 1.0
AN3 CA Uterus Endometric carcinoma 0.5
MES-SA Uterus Uterine sarcoma 0.7
MES-SA/Dx5 Uterus Uterine sarcoma, MDR 1.5
HepG2 Liver Hepatocellular carcinoma 4.4
DU 145 Prostate Carcinoma 9.1
MIA PaCa-2 Pancreas Carcinoma 3.7
SKOV-3 Ovary Adenocarcinoma 13.5
Mean 3.8
Median 1.5
pounds CYC1–CYC3 (see below). Modeling studies sug- X-Ray Structures of Four CDK2-Ligand Complexes
The refinement statistics of the four CDK2-ligand com-gested that substitution of the pyrimidin-2-yl amino
group, as in CYC3, but with an aromatic group bearing plex structures, CDK2/CYC1–CYC4, as well as our holo-
enzyme structure, are shown in Table 4. Details of thean electron-rich substituent, would enable additional
binding interactions with a part of the CDK2 ATP purine CDK2-ligand interactions are summarized in Tables 5
and 6. The protein structure in all ligand complexes isbinding pocket not occupied by CYC1–CYC3. It was, in
fact, found that this compound was more potent as a similar to the apoenzyme. The ligand binding site is
located at the ATP binding site in the cleft between theCDK2 inhibitor than were CYC1–CYC3, as well as pos-
sessing enhanced cellular activity (Table 2). CYC4 was small N-terminal lobe (residues 1–86) and the larger, helical
C-terminal lobe (residues 87–298) (Figures 2 and 3).also subjected to selectivity screening on a panel of30
protein kinases representative of most signaling path- The electron density maps of CDK2 are clear, with
the exception of residues 36–41, which are disorderedways. The following kinases were inhibited to a signifi-
cant extent (80% inhibition at 10 M compound con- in all structures. There is an interesting variation in the
disorder of residues 150–165 (T loop region) and resi-centration and 10 M ATP concentration): CDK1, CDK2,
CDK4, JNK11 (c-Jun N-terminal kinase), SGK (serum- dues 10–15 in the five structures presented here. The
disorder depends on the nature of the interactions be-and glucocorticoid-induced kinase), GSK3 (glycogen
synthase kinase), and LCK (lymphocyte kinase). The ac- tween ligand and protein and is discussed later. Com-
parison of the conformations of the four inhibitor-com-tivity profile of CYC4 against a panel of human tumor
cell lines is shown in Table 3. Furthermore, compound plexed CDK2 structures and the apo-CDK2 structure
gives a root-mean-square fit for corresponding atomsCYC4 was able to significantly slow down tumor growth
in an MES-SA mouse xenograft model [13]. of between 0.3 A˚ and 1.3 A˚.
Table 4. X-Ray Data Collection and Structure Refinement
CDK2 CDK2/CYC1 CDK2/CYC2 CDK2/CYC3 CDK2/CYC4
Resolution (A˚) (outer shell) 20–1.95 (1.98–1.95) 20–1.95 (1.98–1.95) 20–2.3 (2.34–2.30) 20–2.8 (2.98–2.8) 16.5–2.5 (2.66–2.5)
Unit cell P212121 ( 	  	 
 	 90) a 	 53.687 a 	 53.499 a 	 53.736 a 	 52.744 a 	 52.709
b 	 71.799 b 	 71.404 b 	 71.704 b 	 71.948 b 	 71.575
c 	 72.032 c 	 72.356 c 	 72.199 c 	 70.525 c 	 70.429
Total observed 222,716 253,672 151,851 20,559 32,921
Unique 20,576 20,770 12,709 6,931 9,556
Multiplicity 10.45 12.05 11.7 3.0 3.4
Rmerge (%) (outer shell) 7.3 (23.5) 7.8 (24.4) 3.9 (14.4) 8.9 (59.7) 5.7 (26.6)
I/(I) (outer shell) 16.5 (5.61) 17.9 (6.61) 20.54 (5.37) 7.8 (1.1) 9.8 (2.60)
Completeness (%) (outer shell) 97.1 (98.4) 98.8 (100) 98.5 (98.7) 99.3 (99.3) 99.2 (99.2)
Rwork (%) 21.3 20.3 20.9 20.8 20.4
Rfree (%) 24.9 25.1 27.1 26.6 24.9
Rms bonds (A˚)/angles (o) 0.005/1.2 0.005/1.2 0.006/1.3 0.007/1.2 0.007/1.2
Refined ligand occupancy (%) — 73 81 69 59
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Table 5. Protein to Ligand Distances Less Than or Equal to 3.7 A˚
CDK2 Atom/Distance (A˚)CYC1
Residue Atom CYC2 CYC3 CYC4
Ile10 CG2 S4A/3.67 N7/3.30 C1B/3.58
CG2 C8/3.36 C2B/3.41
CG2 N3/3.27
CD1 O10/3.17
O C3B/3.65
Glu12 O CL7A/3.56
Val18 CG1 C4A/3.65 S4A/3.50
Ala31 CB N1/3.53 N1/3.50 C5/3.39
CB C2/3.50 C2/3.36 C6/3.58
CB N7/3.49 N7/3.47
Lys33 CE N3/3.46
NZ N3/3.25 N3/3.29
NZ C1A/3.40
NZ C5A/3.64 C5A/3.67
NZ CL6A/3.26
Val64 CG1 N7/3.63 N7/3.67
Phe80 CG C6A/3.61
CD2 C6A/3.41
CE2
CZ
Glu81 O N7/2.96 N7/2.86 C5/3.69
O C6/3.31 C6/3.31
Phe82 CA C6/3.70 C6/3.20
CA N1/3.62
C N1/3.68
CD1 C6/3.64 N1/3.55
CD1 N7/3.63
CE1 N7/3.29
CE1 O10/3.31
CZ O10/3.30
Leu83 C N1/3.66 N1/3.55
CA N1/3.69 N1/3.64
N N1/3.64 N1/3.30 N1/2.82 N1/2.92
N C6/3.35 C6/3.20
O N1/3.70 N1/2.84 N1/2.72
O C2/3.02 C2/3.08
O C6/3.36 C6/3.25
O N7/2.54 N7/2.58
O C8/2.88 C1B/3.57
O N9/3.35
O O10/3.65
His84 C N9/3.28
C O10/3.58 C6B/3.35
O N9/3.00 C5B/3.50
O O10/3.18 C6B/3.17
Gln85 N C6B/3.53
CA C6B/3.54
Asp86 CG F9B/3.44
OD1 F9B/3.36
OD2 F9B/3.03
OD2 C4B/3.58
OD2 C3B/3.07
Lys89 CB F9B/3.31
CG F9B/3.54
CE F9B/3.06
Leu134 CD1 N1/3.42
CD1 C2/3.29 C2/3.30
CD1 N3/3.50 N3/3.43 N3/3.66
CD1 C4/3.70 C4/3.37
CD1 C5/3.20 C5/3.39
CD1 N7/3.59 N7/3.33 C6/3.58 C6/3.68
CD2 N3/3.51
Ala144 CB CL6A/3.48 C6A/3.67 C6A/3.53
Asp145 CG N2A/3.19
OD1 C1A/3.54 C1A/3.48
OD1 N2A/3.05 N2A/2.78
OD1 C6A/3.11 C6A/3.27
OD2 N2A/3.03
OD2 C3A/3.45
OD2 C7A/3.25
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that may be displaced on ligand binding. Only five waterTable 6. Interaction Energies between Ligand and ATP Binding
Pocket Residues in kcal/mol, Calculated with InsightII molecules were included in the published apo-CDK2
structure (Protein Data Bank code 1HCL) [14]. For eachCDK2 Residue CYC2 CYC3
ligand an X-ray refinement was therefore carried out in
Ile10 1.2 1.5 which the water molecules of the apo-CDK2 structure
Gly13 0.9 0.1
were included along with the ligand. Constraints wereThr14 0.2 0.0
applied such that the total occupancy of water plusTyr15 0.2 0.3
ligand must equal 100%. Disordered conformations ofVal18 2.3 1.8
Lys33 5.4 4.1 certain active site side chains (particularly Lys33 and
Phe80 0.9 1.5 Asp145) were also constrained in the same way. Refine-
Glu81 1.2 2.7 ment results (Table 4) suggest that the four ligands have
Phe82 2.2 1.7
occupancies of between 60% and 80%.Leu83 2.0 0.9
Gln85 0.1 1.2
Asp86 1.7 5.7 Evaluation of the Ligands Selected by LIDAEUS
Lys89 2.0 0.5
Compounds CYC1–CYC3 were initially selected by theGln131 0.7 0.5
program LIDAEUS, with the X-ray structure from theAsn132 0.7 1.0
CDK2-staurosporine complex as a template. A moreLeu134 0.8 1.6
Ala144 0.7 1.2 detailed evaluation of the docking modes determined
Asp145 2.0 2.4 by the program was then carried out with the refined
CDK2 45.3 55.9 X-ray structure of the CYC1/CDK2 complex as a tem-
plate. A total of 184 site points were generated in the
binding site. The final refined conformation of CYC1, as
The electron density maps of all ligands bound in the determined in the X-ray structure, shows a significant
active site are clear, and the models of these com- twist of 35 about the bond linking the two aromatic
pounds fit well (Figure 4). Careful refinement of the li- rings. The model structure of the ligand used in the
gands suggested that the sites are only partially occu- small-molecule database was, however, planar. The ef-
pied. The apo-CDK2 X-ray structure shows that the fect of the two different ligand conformations was exam-
active site contains nine well-defined water molecules ined by allowing LIDAEUS to fit both conformers into
the binding site. The fitting algorithm, which matches
selected ligand atoms onto site points, found 23 initial
ligand positions of the flat and twisted CYC1 models.
Of these, 13 had an initial score below the target energy
threshold. Rigid-body least-squares energy minimiza-
tion of these hits led to three ligand positions with good
scores (Figure 5). The minimized model structures all
adopt positions that are similar to the experimentally
determined X-ray structure. The relative energy scores
of the three hits are 23.8, 22.5, and 19.9 (arbitrary
units), with corresponding rmsd coordinate errors of
1.60, 1.58, and 3.42 A˚. The one planar ligand model
found to give an acceptable energy score gives the
worst fit and indicates the importance of even small
conformational changes in the ligand for efficient dock-
ing (Figure 5). The current flexible docking facility in
LIDAEUS will rotate the ligand about single bonds, but
only to satisfy well-defined H bonding possibilities. The
fourth ligand position (Figure 5) shows the next-best fit
of the ligand, which has a relative energy score of 136.4
and an rmsd coordinate error of 4.57 A˚. This relative
score places this ligand position outside the acceptable
range.
Comparison of CDK2 ATP Antagonist
Binding Modes
There are now over fifteen literature examples of X-ray
structures of small-molecule inhibitors complexed with
CDK2 (reviewed in [1, 15]). The IC50 values for these
Figure 2. Overall Architecture of CDK2
inhibitors range from the micromolar to the low-nanomo-
N-terminal domain (residues 1–86), blue; C-terminal domain (resi- lar range. All bind in the narrow cleft between the N- and
dues 87–298), red; the T loop (residues 150–165), residues 10–15,
C-terminal domains of CDK2 and overlap to a greater orand the linker residues Glu81, Phe82, and Leu83, green. The disordered
lesser degree with the site occupied by the adenine ringresidues 38–41 are shown as a dotted line. Ligand CYC1 is shown
bound in the ATP binding pocket. in the ATP complex. The width of this binding groove
is determined by the hydrophobic side chains of Ile10,
Structures of a Novel Family of CDK2 Inhibitors
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Figure 3. Close-up of the ATP Binding
Pocket
Sidechains of Lys33, Asp145, Tyr15, and Thr160
are shown for the CYC1 complex structure.
The alternative conformations found in the
CYC3 structure are also shown. The T loop
is not visible in the CYC3 structure. The move-
ment of the loop containing Tyr15 to the T loop
is shown by a dotted line.
Val18, and Ala31 that point “down” from the N-terminal When the exocyclic primary amine group of the purine
(as in ATP) or pyrimidine (as in CYC1 and CYC2) ringsdomain, and Leu134, which points “up” from the C-ter-
minal domain. Thus, a binding feature common to most is further substituted, the bulk of such a substituent
apparently precludes this binding mode. However, anknown inhibitors is the interaction between the methyl
groups of these side chains pointing into both sides of alternative H bonding pattern (mode 2) can be achieved,
where the NH and carbonyl of Leu83 act as donor andthe  electron clouds of the planar aromatic groups of
the inhibitors (Figures 2 and 4). acceptor in a manner reminiscent of antiparallel H bond-
ing between  strands. A third favorable CH…O interac-The boundary wall of the binding cleft is formed by
the  strand (Phe80, Glu81, Leu83, and His84) (Figure 4), tion is formed between an aromatic H atom of the ligand
and the carbonyl of Glu81 (Table 1). Ligand-CDK2 com-which links the N- and C-terminal domains. In all cases
the inhibitors form two or three specific H bonds with plexes showing this mode of H bonding include CYC3
and CYC4 (this work), purvalanol B [17], H717 [18], ros-the backbone amide groups of Glu81 and Leu83. There
are essentially two major H bonding patterns. One (H covitine [19], and OL567 [20].
In the H bonding mode observed with CYC3, it is likelybonding mode 1), shown in the ATP complex [14], in-
volves the carbonyl of Glu81 and the NH of Leu83 acting as that interactions of the pyrimidin-2-yl amine substituent
provide supplementary binding energy, making this po-the donor-acceptor pair for complementary H bonding
donors and acceptors on the ligand (Table 1). The third sitioning possible. This can be inferred from the observa-
tion that CYC3, which does not have the hydroxy-imineinteraction in this mode is an energetically favorable
interaction between C-H and the carbonyl of Leu83. Mode group present in the corresponding thiazolopyrimidine
CYC2, does not assume this interaction mode. The addi-1 is found, e.g., in CDK2 complexes with ATP [14], CYC1,
CYC2 (this work), and flavopiridol [16] (compare Table 1). tional contacts in the substituted amine stabilize H
Figure 4. The Electron Density Maps of Apo-CDK2, CYC1, CYC2, CYC3, and CYC4, with H Bonds as Dotted Lines
Apo-CDK2, CYC1, and CYC2 contoured at 1 ; CYC3 and CYC4 contoured at 0.9 .
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subsite and Val18, which contacts the ribose of ATP) and
that form complementary binding contacts with nano-
molar ATP antagonists. In addition, optimal interactions
with Phe80 are not observed in CYC1; however, they
are seen in several CDK2 complexes published to date,
including those with oxindole and purvalanol B.
Examination of the complex of CYC2 indicates a very
similar binding mode to that of CYC1, with the 2-fold
decrease in potency presumably resulting from less-
optimal contacts of the dichloro-thiophene group com-
pared with those of the dimethyl-thiazole heterocyclic
system.
The complex of CYC3 with CDK2 indicates a surpris-
ing switch in the mode of interaction with the ATP cleft,
which may explain the 6- to 7-fold increase in CDK2
inhibition of this analog. The result of this alternate mode
is that the pyrimidine and thiazole rings make more ef-
fective contacts with the base of the cleft. In particular,
Figure 5. Overlay of the Top Four Positions Identified by the Pro- the pyrimidine ring interactions with Ile10, Ala31, and Leu134
gram LIDAEUS, in Green, Compared with the Experimentally Deter-
are energetically more favorable (Table 6). The thiazolemined X-Ray Structure of CYC1
heterocycle complementarity with the ribose binding
The ligand in red is the fourth-best fit. It has an unacceptable energy
residues is increased, and, additionally, one of thescore (and large rmsd fit on the experimental structure).
methyl groups interacts with Phe80. This important ener-
getically favorable interaction (as indicated by the 0.6
kcal/mol increase in binding energy of CYC3 with Phe80)bonding mode 2 and enable hydrophobic contacts of
occurs between the methyl substituent of the thiazolethe ligand, i.e., one of the thiazole methyl groups, with
that points toward the face of the aromatic side chain.Phe80. In particular, the hydroxyl function of CYC3 partic-
This interaction, which occurs in both CYC3 and CYC4,ipates in an H bond to the side chain of Asp86. The
is similar to the well-documented weak electrostatic in-nonbonded energy provided by this contact results in
teractions discussed for aromatic groups [24]. In addi-the addition of 3 kcal/mol relative to CYC2 (Table 6).
tion to this contact, displacement of a water moleculeThis stabilizing contact thus provides the driving force
(observed in the CYC1- and ATP-complexed CDK2for the switch in H bonding mode, which, in turn, pro-
structures) likely results in the entropic contribution tomotes more-favorable hydrophobic interactions.
the binding.Some inhibitor ligands form conventional NH…O hy-
As the observation was made that substitution on thedrogen bonds with all three sites; these include indirubin
2-amino group could be tolerated and, in fact, resultedsulphonate [6], NU2058 [21], and oxindole [22], while
in an increase in potency, further analogs were synthe-the substituted 4-anilinoquinazoline family forms only
sized with bulky substituents at this position [25]. Oneone conventional NH…N hydrogen bond, with the two
such analog, CYC4, was generated and shown to havecarbonyl sites forming (presumably weaker) O…HC in-
enhanced inhibition of CDK2/cyclin E (0.9M). The X-rayteractions with the aromatic group of the ligands.
structure of this analog confirmed the presence of HThose ligands (including CYC3 and CYC4) having
bonding mode 2 and indicates that the potency en-bulky substituents that point out toward the entrance
hancement (relative to CYC3) results from additionalto the binding cleft can interact with a number of polar
contacts from the trifluoromethylphenyl substituent toside chains lining the cleft. In particular, Lys89 is found
the side chain of Asp86. From these results it could beto form electrostatic interactions with aromatic groups,
envisaged that further optimization of the contacts madeas found with the chlorophenyl ring of flavopiridol. Thio-
with Asp86 and Lys89 could increase the potency of thisand oxoflavopiridol analogs are selective CDK1 inhibi-
ligand series. In addition, derivatization of the thiazoletors, with IC50 values of 130 nM [16] and 2-fold and 50-
in order to make interactions with the ribose and phos-fold selectivity over CDK2 and CDK4, respectively. The
phate binding residues could lead to enhancements inpyrido-pyrimidin-7-one inhibitors from Parke-Davis [23]
ATP antagonism.also show some specificity for CDK4 inhibition and have
the large side chain projecting out of the cleft toward
solution.
Lys33 and Asp145 Act as a Trigger for Conformational
Change in the T Loop
Full activation of CDK2 is achieved by binding a cyclinProtein-Ligand Contacts: Implications
for Inhibitor Design partner and through phosphorylation of Thr160, both of
which invoke significant conformational changes. In theProtein-ligand contacts are summarized in Tables 5 and
6. In the CYC1 complex there are several interactions cyclin-bound conformation of CDK2, there are major
changes in both the activation loop (which undergoeswith the hydrophobic binding cleft; however, many con-
tacts observed in high-affinity CDK2 ligands are not a 23 A˚ shift) and in the position of the 45PSTAIRE51 helix
[26]. Movement of the T loop to make contacts withoptimal in this binding mode. These include interactions
as mentioned above (Ile10, Ala31, and Leu134 in the purine the cyclin subunit exposes the ATP binding site, while
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rotation of the PSTAIRE helix results in the side chain A novel 2-arylamino-4-thiazolopyrimidine compound
(CYC4) was designed on the basis of these results. Thisof Glu51 being positioned to form a salt bridge with Lys33
and properly orienting the ATP phosphates for catalysis compound had enhanced inhibitory potency, with an
IC50 value of 0.9M for CDK2 inhibition, and also showed[27]. Significantly, two of the key residues, Lys33 and
Asp145, which are affected by these activating changes, 6-fold specificity over inhibition of CDK4. Antiprolifera-
tive activity for transformed cells was also significantlyare frequently involved in direct binding to a number of
the inhibitors. The four CDK2 complexes presented in better than for normal cells. These results identify CYC4
as an excellent lead molecule for further development.this work help to identify a correlation between the con-
formation adopted by Lys33 and Asp145 and the degree An important feature of the CDK mechanism is the
large conformational change of the activation loop thatof disorder in the T loop.
Of the available (not cyclin-bound) X-ray structures occurs on activation by cyclin binding and phosphoryla-
tion of Thr160. Two distinct binding modes for the fourof CDK2, only the following four have a reasonably well-
ordered T loop with well-defined electron density for the ligands are determined by the substitution pattern of
the pyrimidine ring. One mode shows an identical H(unphosphorylated) Thr160 residue. These are the apo-
CDK2 structure (Figure 4) and complexes with CYC1, bonding pattern to that of bound ATP. For these struc-
tures the side chains of Lys33 and Asp145 form H bondsCYC2, ATP, and NU2058 (Protein Data Bank code 1E1V).
In each of these structures, Lys33 adopts a gauche con- or salt bridges deep in the active site, and the activation
T loop is well ordered. In the alternative binding mode,formation and points “down” to make a direct salt bridge
with Asp145 (Figure 3). In contrast, all other published the ligand induces a conformational change in the side
chains of both Lys33 and Asp145. This triggers a series ofinhibitor complexes show the side chain of Lys in the
trans conformation pushed “up” by the bulk of the bound further conformational changes resulting in a rearrange-
ment and “melting” of the T loop. Our analysis suggestsligand. This movement (which is shown by the more
favorable interaction energy of Lys33 with CYC2 than a mechanism showing how the activation loop can be
disordered solely by ligand binding. These changes inwith CYC3 in Table 6) repositions or breaks the salt
bridge with Asp145, which also frequently adopts a signifi- CDK2 conformation on inhibitor binding may affect
CDK2-cyclin interaction and contribute toward inhibitioncantly different conformation (Figure 3). The new confor-
mations of Lys33 and Asp145 have a knock-on effect and of kinase activity.
cause a reorientation of neighboring side chains. In par-
ticular, the close contact between the side chains of Experimental Procedures
Asp145 and Tyr15 results in an induced movement of the
Expression and Purification of CDK2adjacent Thr14 and a significant shift of the glycine-rich
Recombinant human CDK2 (SWISS-PROT primary accession num-loop. This movement is the likely cause of further confor-
ber P24941) was expressed with an Hi5 insect cell/baculovirus sys-
mational rearrangement of the adjacent T loop (Figure tem. In a typical preparation 400 ml of Hi5 cell culture (0.7–1  109
3). This observation suggests that it is not only phos- cells) were infected with CDK2 virus (three plaque-forming units per
phorylation of Thr160 that invokes the conformation cell). After 2 days culture at 28C, cells were harvested by centrifuga-
tion and were resuspended in lysis buffer, 10 mM Tris (pH 7.5), 25change and melting of the T loop but that movements
mM NaCl, 1 mM EDTA, 2 mM DTT, and protease inhibitor cocktailcaused by ligand binding may also play a role. Recently,
(Sigma, P8340). After sonication the lysate was clarified by centrifu-examples have emerged in the literature illustrating that
gation for 30 min at 100,000  g and 4C. The supernatant was
the mechanism of action of some kinase inhibitors is to passed through Vivapure Maxi Q columns (Vivscience) by centrifu-
bind preferentially to the inactive form of the enzyme gation for 5 min at 3,500 rpm and 4C; the flowthrough was loaded
[28, 29]. A recent study of the affinity of inhibitors for onto ATP-agarose (Sigma; A2767), preequilibrated with buffer (10
mM HEPES [pH 7.5], 25 mM NaCl, 0.5 mM DTT, 1 mM EDTA, and 10%CDK2 alone versus the CDK2/cyclin A complex indicates
glycerol). After washing, bound protein was eluted with a stepwisetighter binding to the monomeric protein [30]. Our analy-
increase of NaCl concentrations in buffer. The fractions containingsis suggests that the additional strength of binding in
CDK2 (typically eluted at 50–100 mM NaCl) were pooled, concen-
the inactive form may be attributed to the ability of the trated to approximately 7 mg/ml, and loaded onto a Superdex 75
inhibitor to induce CDK2 conformations that would be column (Pharmacia), preequilibrated with buffer (25 mM Tris [pH
less accessible when CDK2 is bound to cyclin. 7.5], 100 mM NaCl, 1 mM DTT, and 1 mM EDTA) at a flow rate of
1 ml/min. Fractions containing CDK2 were concentrated to 8–10
mg/ml by ultrafiltration (Millipore ultrafiltration units, 10 kDa cutoff
membrane), and the buffer was exchanged to 10 mM HEPES (pHBiological Implications
7.4), 25 mM NaCl, and 1 mM EDTA [31] and used for 3D crystalli-
zation.
Inhibitors of CDK2 block cell division and may provide
a useful and specific cancer therapy. Successful drug
Crystallization and Structure Determinationmolecules must show specificity and potency by prefer-
The CDK2 crystals were grown by vapor diffusion by the hanging
entially inhibiting CDK2 over the other structurally related drop method. Typically, a 2 l solution of CDK2 (7–8 mg/ml in the
kinases in the cell. We have applied a new virtual screen- final purification buffer) was mixed with a 2 l well solution. The
precipitant solution contained 15% PEG 6000 and 100 mM Na-ing program (LIDAEUS), which rapidly fits each potential
HEPES buffer (pH 7.8–8.2). An alternative precipitant contained 12–ligand in a 3D-encoded small-molecule database into
25% PEG 3350 and 200 mM potassium acetate (or 200 mM lithiumthe defined binding region of CDK2. This approach has
acetate or 200 mM sodium fluoride) and gave crystals of similarled to the discovery of a new class of 2-amino-4-thiazolo-
quality. Crystals were obtained after 3–5 days at 4C. Ligand com-
pyrimidine CDK2 inhibitors. CDK2 modulation by the plexes of CYC2 were prepared by soaking native CDK2 crystals for
three compounds selected by screening (CYC1–CYC3) up to 2 hr in a solution comprising 5 mM inhibitor, 20% PEG 6000,
and 100 mM HEPES at pH 7.8. The solution was prepared by dilutingwas verified biochemically and by X-ray crystallography.
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a concentrated (100 mM) solution of ligand in DMSO with the crystal chelate affinity chromatography to90% homogeneity) or recombi-
nant active ERK-2 (Upstate Biotechnology). The assays buffer con-mother liquor. For the less water-soluble compounds CYC3 and
CYC4, the following procedure was used. Crystals were equilibrated sisted of 25 mM -glycerophosphate, 20 mM MOPS, 5 mM EGTA,
1 mM DTT, and 1 mM Na3VO3 (pH 7.4) into which were added 2–4in a solution of 20% PEG 4000, 100mM HEPES at pH 7.4, and 15mM
NaCl for 20 min. The crystals were then transferred through solutions g of active enzyme with appropriate substrates (purified histone
H1 for CDK2, recombinant GST-retinoblastoma protein [residuesof increasing PEG concentration in steps of 5% (up to 40%) and
equilibrated for 20 min at each step. The final drop consisted of 773–928] for CDK4, and myelin basic protein for ERK-2). Inhibitors
were made up in 10% aq DMSO, and 10 l of the solutions was40% PEG, 100 mM HEPES at pH 7.4, 15 mM NaCl, 5% DMSO, and
1mM ligand. Crystals were left to soak under these conditions for added to wells. Final reaction volume was 50 l. The reaction was
initiated by addition of Mg/ATP mix (15 mM MgCl2 plus 100 M ATP3 days (CYC3) and 28 days (CYC4). Crystals of the CYC1/CDK2
complex could not be obtained by soaking, and cocrystallization with 30–50 kBq per well of [
-32P]-ATP), and the mixtures were
incubated for 10 min (CDK2/cyclin E and ERK-2) or 45 min (CDK4/was used. Typically, 50 l CDK2 (8.0 mg/ml in final purification
buffer) was mixed with 0.5 l CYC1 (100 mM in DMSO), and the cyclin D1), as required, at 30C. Reactions were stopped on ice,
and then the mixtures were filtered through p81 filterplates or GF/Ccomplex solution was then centrifuged for 15 min. The supernatant
solution was withdrawn carefully by pipette and used for crystalliza- filterplates (for CDK4) (Whatman Polyfiltronics). After washing three
times with 75 mM aq orthophosphoric acid, plates were dried, scin-tion trials.
Crystals of about 0.05 mm in length were mounted in 0.05–0.1 tillant (Microscint 40) was added, and incorporated radioactivity was
measured with a scintillation counter (TopCount; Packard Instru-mm cryoloops (Hampton Research). The crystals were immersed
briefly in a cryoprotectant and then flash-frozen in liquid nitrogen. ments, Pangbourne, Berks, UK). Data was analyzed with curve-
fitting software (GraphPad Prism version 3.00 for Windows;Equally effective cryoprotectants were 30% glycerol or 100% im-
mersion oil. All diffraction data (Table 4) were collected at 100 K GraphPad Software, San Diego, CA) to determine IC50 values (con-
centration of test compound that inhibits kinase activity by 50%.).(Cryostream; Oxford Cryosystems). Data for CDK2 complexes of
CYC1 and CYC4 were collected at the Daresbury synchrotron facility Recombinant human PKC kinase activity was measured simi-
larly, by the incorporation of radioactive phosphate into histone H3.on stations 14.1 and 9.6 with an ADSC Quantum4. The complex
with CYC2 was collected with a rotating anode generator (Nonius The reaction mixture (total volume of 65 l) consisted of 50 mM
Tris-HCl, 1 mM calcium acetate, 3 mM DTT, 0.03 mg/ml phosphati-FR571). Data for the complex with CYC3 was collected at DESY,
Hamburg, on station BW7A with a MAR CCD detector. Data pro- dylserine, 2.4g/ml PMA, 0.04% NP40, 12 mM MgCl2, purified PKC
(100 ng; Upstate Biotechnology), histone H3 (0.2 mg/ml), and ATPcessing was carried out with the programs DENZO and SCALEPACK
[32]. ARP/wARP [33] was used for initial density interpretation and mix as above. The reaction was carried over 15 min at 37C on a
microplate shaker and was stopped by adding 10 l 75 mM aqthe addition of water molecules. The programs CNS [34], REFMAC
[35], and SHELX97 [36] were used for structural refinement. A num- orthophosphoric acid and placing the plate on ice.
The remaining kinase assays (c-raf, MEK1, RSK2, MKK6, SPK2a/ber of rounds of refinement and model building with the program
O [37] were carried out. Calculation of protein-ligand interaction p38, SAPK2b/p38/2, SAPK3/p38
, SPK4/p37, MAPKAP-K2,
MSK1, MKK4, MKK7, JNK11, JNK22, PDK1, SGK, GSK3, PKA,energies for the CDK2 inhibitors was performed with the program
CDISCOVER after addition of hydrogens and steepest-descent minimi- ROCK-II, CK2, LCK, PRAK, p70S6K, CHK1, and PKB) were carried
out by Upstate Discovery, Dundee, UK, essentially as describedzation with the modeling package InsightII (Accelrys, San Diego, CA).
[40]. The ATP concentration used in these assays was 10 M.
Database Mining
The program LIDAEUS was used to select compounds from the
MTT Cytotoxicity AssayMaybridge available compounds database. The program exhaus-
Standard MTT (thiazolyl blue; 3-[4,5-dimethylthiazol-2-yl]-2,5-diphe-tively fits each ligand in the defined binding region. Initial orienta-
nyltetrazolium bromide) assays were performed [41]. In short, cellstions are obtained by fitting ligand atoms of appropriate type onto
were seeded into 96-well plates according to doubling time andthe grid defining the binding region. After the initial placement of the
incubated overnight at 37C. Test compounds were made up inligand, multiple conformers are generated to see whether alternative
DMSO, and a 3-fold dilution series was prepared in 100 l cellligand conformations would provide more favorable binding. Finally,
medium, added to cells (in triplicates), and incubated for 72 or 96a least-squares energy minimization of each ligand orientation is
hr at 37C. MTT was made up as a stock of 5 mg/ml in cell medium,carried out to provide a ranking score. The scoring function accounts
for van der Waals, hydrophobic, and H bonding interactions. The and the solution was filter sterilized. The medium was removed from
template for the database-mining studies was the ATP binding site cells and washed with 200 l/well PBS. MTT solution was then
of the X-ray structure of the complex of CDK2 with staurosporine added at 20 l/well and incubated in the dark at 37C for 4 hr. MTT
(Protein Data Bank code 1AQ1). solution was removed, and cells were again washed with 200l PBS.
MTT dye was solubilized with 200 l/well of DMSO with agitation.
Absorbance was read at 540 nm, and data was analyzed with curve-Chemistry
fitting software (GraphPad Prism) to determine IC50 values. The cellCompounds CYC1, CYC2, and CYC3 were obtained from Maybridge
lines used were obtained from the ATCC (American Type CultureChemical Company, Tintagel, Cornwall, England (compound codes
Collection, Manessas, VA).CD 09770, CD 09763, and CD 09767). Compound CYC4 was synthe-
sized by the general method of Bredereck [38]. In short, 5-acetyl-
2,4-dimethylthiazole was converted to the enaminone with the aid of
AcknowledgmentsN,N-dimethylformamide diethyl acetal [39]. This was then condensed
at elevated temperature under basic conditions in 2-methoxyethanol
with the guanidine nitrate derived from 4-(trifluoromethyl)aniline [25]. The authors would like to express their gratitude to the following
The isolated product was purified by silica gel chromatography with colleagues at Cyclacel for their contributions to the work presented
an ethyl acetate/hexane solvent system. CYC4 was obtained as an here: Susan Barker, David Blake, Helen Cox, Mairi Mackenzie (mo-
orange solid, m.p. 183C–185C. Identity and purity (97.5%) were lecular biology and protein biochemistry), Susan Duff, and Nikolai
assessed by various analytical methods (1H- and 13C-NMR, LC-MS, Zhelev (cell biology). We thank the CLRC, Daresbury, and DESY,
and combustion analysis). Hamburg, for X-ray data collection facilities and the Edinburgh Pro-
tein Interaction Centre (EPIC) for use of equipment.
Kinase Assays
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